SEGMENTS - Summarized Financial Information by Segment (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
SEGMENTS [Abstract]
Revenues		$ 134,224	$ 119,839	$ 371,010	$ 308,905
Cost of product revenue		58,598	60,180	167,061	152,685
Research and development		1,528	412	3,386	1,422
Plasma center operating expenses		1,272	1,021	3,710	2,968
Amortization of intangible assets		38	28	93	363
Consolidated selling, general and administrative expense		21,776	18,560	68,068	50,807
Other expense, net		(3,497)	(2,889)	(7,631)	(9,659)
Income (loss) before taxes		47,515	36,749	121,061	91,001
Unallocated interest expense, primarily related to interest on senior debt (see Note 6)		1,675	3,499	5,484	11,051
Unallocated interest income		376	666	1,384	1,499
Loss on extinguishment of debt		(2,177)	0	(3,336)	0
Total assets		568,687	390,618	568,687	390,618	$ 488,678
Operating Segments [Member]
SEGMENTS [Abstract]
Revenues		134,188	119,803	370,902	308,797
Cost of product revenue		58,598	60,180	167,061	152,685
Research and development		1,528	412	3,386	1,422
Plasma center operating expenses		1,272	1,021	3,710	2,968
Selling, marketing and distribution		8,150	5,900	17,827	13,374
Amortization of intangible assets		38	28	93	363
General and administrative expense		14,585	3,988	44,688	18,276
Other expense, net		(21)	(56)	(195)	(107)
Income (loss) before taxes		49,996	48,218	133,942	119,602
Expenditures for additions to long-lived assets		14,944	1,076	21,629	5,825
Total assets		430,945	299,647	430,945	299,647
Reconciling Item [Member]
SEGMENTS [Abstract]
Revenues		36	36	108	108
Income (loss) before taxes		36	36	108	108
Unallocated interest expense, primarily related to interest on senior debt (see Note 6)		(1,675)	(3,499)	(5,484)	(11,051)
Unallocated interest income		376	666	1,384	1,499
Loss on extinguishment of debt		(2,177)		(3,336)
Corporate [Member]
SEGMENTS [Abstract]
General and administrative expense	[1]	(959)	8,672	5,553	19,157
Income (loss) before taxes	[1]	959	(8,672)	(5,553)	(19,157)
Total assets	[2]	137,742	90,971	137,742	90,971
ADMA BioManufacturing [Member] | Operating Segments [Member]
SEGMENTS [Abstract]
Revenues		134,188	117,719	369,852	304,016
Cost of product revenue		58,406	58,156	166,220	147,619
Research and development		1,528	412	3,386	1,422
Plasma center operating expenses		0	0	0	0
Selling, marketing and distribution		8,150	5,900	17,827	13,374
Amortization of intangible assets		38	28	93	363
General and administrative expense		14,585	3,988	44,688	18,276
Other expense, net		(21)	(56)	(195)	(103)
Income (loss) before taxes		51,460	49,179	137,443	122,859
Expenditures for additions to long-lived assets		14,652	1,067	21,366	5,720
Total assets		403,917	266,456	403,917	266,456
Plasma Collection Centers [Member] | Operating Segments [Member]
SEGMENTS [Abstract]
Revenues		0	2,084	1,050	4,781
Cost of product revenue		192	2,024	841	5,066
Research and development		0	0	0	0
Plasma center operating expenses		1,272	1,021	3,710	2,968
Selling, marketing and distribution		0	0	0	0
Amortization of intangible assets		0	0	0	0
General and administrative expense		0	0	0	0
Other expense, net		0		0	(4)
Income (loss) before taxes		(1,464)	(961)	(3,501)	(3,257)
Expenditures for additions to long-lived assets		292	9	263	105
Total assets		$ 27,028	$ 33,191	$ 27,028	$ 33,191

[1] - Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.

[2] - Primarily consists of cash and deferred tax assets.